Torrent Pharmaceuticals to Launch Semaglutide in Brazil
The pharmaceutical company expects to enter the Brazilian market with its diabetes treatment in the next six to nine months.
Updated on Oct. 25, 2026 in Diabetes
Live Poll
Do you support pharmaceutical companies expanding the availability of generic drugs to international markets?
Torrent Pharmaceuticals plans to introduce its semaglutide treatment to Brazil within the next 6-9 months to expand its international business presence. This expansion follows a period of strong financial growth for the company in the region.
Why it matters
Entering the Brazilian market represents a strategic effort to capitalize on the increasing global demand for diabetes therapies. This move builds upon the company's established success in India where it holds a significant share of the semaglutide market.
Torrent Pharmaceuticals reported Q2 revenue of 440 crore rupees, or 236 million Brazilian reais, in the Brazil market. The company currently maintains 53 products under regulatory review by ANVISA.
The players
Torrent Pharmaceuticals
This is an Indian multinational pharmaceutical company that specializes in therapeutic areas including diabetes and cardiovascular care.
ANVISA
The Brazilian Health Regulatory Agency is responsible for the approval and monitoring of health products, including drugs, within Brazil.
The details
The firm recently restored semaglutide supplies in India by onboarding a new manufacturing partner and currently controls a 32 percent market share there. Meanwhile, the company is preparing for a potential increase in its global medical representative workforce to 9,600 next year.
Timeline
September 2026 saw the company restore semaglutide supplies in India.
Financial results were reported for Q2 FY27.
The launch of semaglutide in Brazil is planned for the next 6-9 months.
The company may expand its medical representative workforce next year.
Health Landscape
This expansion marks a significant step for the company as it navigates the regulatory requirements set by the ANVISA drug registration process to launch new therapies.
The introduction of this treatment could offer patients in Brazil new options for diabetes management within the coming year. Increased availability depends on the successful navigation of current regulatory reviews.
The takeaway
Patients and healthcare providers should monitor regulatory updates regarding the availability of new diabetes treatment options. The company's expansion plans reflect a broader industry focus on scaling supply chains to meet international health needs.
Further reading
Learn more about evolving treatment standards in the Diabetes section.
Source note: This article includes information reported by @businessline.
Live Poll
Do you support pharmaceutical companies expanding the availability of generic drugs to international markets?
